{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:36:28Z","timestamp":1782887788461,"version":"3.54.5"},"reference-count":24,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    There is no published data comparing time to vancomycin de-escalation for patients with respiratory infections screened for methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (MRSA) with nasal culture compared to polymerase chain reaction (PCR).\n                    <jats:bold>Objective:<\/jats:bold>\n                    To compare the duration of vancomycin therapy between patients who underwent MRSA testing via culture vs PCR.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This was an Institutional Review Board (IRB) approved, multi-site, retrospective cohort study which included patients receiving vancomycin therapy for the treatment of pneumonia who underwent MRSA screening with either culture or PCR testing. The primary outcome was total days of vancomycin therapy. Secondary outcomes included length of stay (LOS), incidence of acute kidney injury, and time from nasal swab to vancomycin discontinuation.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 120 patients met inclusion criteria, with 57 in the culture group and 63 in the PCR group. The median duration of vancomycin was significantly shorter in the PCR group compared to the culture group (0.77 vs 1.80 days;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001). The median time from nasal swab collection to vancomycin discontinuation was also significantly shorter in the PCR group compared to the culture group (0.29 vs 1.38 days;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001). There was no difference in the median LOS or the incidence of acute kidney injury (AKI) between groups.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    This is the first study to directly compare duration of vancomycin therapy as the primary outcome for patients who underwent MRSA screening with nasal culture vs PCR. The use of MRSA PCR testing was associated with a significantly shorter duration of vancomycin therapy in patients with pneumonia when compared to culture-based testing.\n                  <\/jats:p>","DOI":"10.1177\/87551225261429822","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:01:53Z","timestamp":1774893713000},"page":"171-175","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Time to Vancomycin De-Escalation in Pneumonia Patients Screened for MRSA Using Culture vs PCR Testing"],"prefix":"10.1177","volume":"42","author":[{"given":"Kayla N.","family":"Wilkinson","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UPMC Mercy, Pittsburgh, PA, USA"},{"name":"Department of Pharmacy at Geisinger Medical Center, Danville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Wein","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Pharmacy, UPMC Mercy, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1314-7239","authenticated-orcid":false,"given":"Pamela J.","family":"McCormick","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UPMC Mercy, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget M.","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UPMC Mercy, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2022.03.009"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2023.444"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir052"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01805-13"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/14-101"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2016.11.008"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.08.011"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.4037\/ajcc2015102"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.233"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1416904"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02432-16"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01326-09"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02022-12"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01745-09"},{"key":"e_1_3_2_18_2","unstructured":"CDC. Core Elements of Hospital Antibiotic Stewardship Programs. US Department of Health and Human Services CDC; 2019. Accessed February 26 2026. https:\/\/www.cdc.gov\/antibiotic-use\/core-elements\/hospital.html"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab099"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0018578719888906"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2020.05.002"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221121144"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/87551225251359508"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13121706"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02972-13"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225261429822","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225261429822","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225261429822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:10:45Z","timestamp":1782882645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225261429822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/87551225261429822"],"URL":"https:\/\/doi.org\/10.1177\/87551225261429822","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}